Literature DB >> 26014424

Attitudes of women of advanced maternal age undergoing invasive prenatal diagnosis and the impact of genetic counselling.

Lea Godino1, Eva Pompilii1,2, Federica D'Anna1, Antonio M Morselli-Labate3, Elena Nardi3, Marco Seri1, Nicola Rizzo2, Gianluigi Pilu2, Daniela Turchetti1.   

Abstract

Despite the increasing availability and effectiveness of non-invasive screening for foetal aneuploidies, most women of advanced maternal age (AMA) still opt for invasive tests. A retrospective cross-sectional survey was performed on women of AMA undergoing prenatal invasive procedures, in order to explore their motivations and the outcome of preliminary genetic counselling according to the approach (individual or group) adopted. Of 687 eligible women, 221 (32.2%) participated: 117 had received individual counselling, while 104 had attended group sessions. The two groups did not differ by socio-demographic features. The commonest reported reason to undergo invasive tests was AMA itself (67.4%), while only 10.4% of women mentioned the opportunity of making informed choices. The majority perceived as clear and helpful the information received at counselling, and only 12.7% had doubts left that, however, often concerned non-pertinent issues. The impact of counselling on risk perception and decisions was limited: a minority stated their perceived risk of foetal abnormalities had either increased (6.8%) or reduced (3.6%), and only one eventually declined invasive test. The 52.6% of women expressed a preference toward individual counselling, which also had a stronger impact on perceived risk reduction (P=0.003). Nevertheless, group counselling had a more favourable impact on both clarity of understanding and helpfulness (P=0.0497 and P=0.035, respectively). The idea that AMA represents an absolute indication for invasive tests appears deeply rooted; promotion of non-invasive techniques may require extensive educational efforts targeted to both the general population and health professionals.

Entities:  

Mesh:

Year:  2015        PMID: 26014424      PMCID: PMC4755368          DOI: 10.1038/ejhg.2015.116

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  17 in total

Review 1.  Screening for fetal aneuploidies at 11 to 13 weeks.

Authors:  Kypros H Nicolaides
Journal:  Prenat Diagn       Date:  2011-01       Impact factor: 3.050

Review 2.  Clinical practice. Prenatal screening for aneuploidy.

Authors:  Deborah A Driscoll; Susan Gross
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

Review 3.  Outcomes and process in genetic counselling.

Authors:  A Clarke; E Parsons; A Williams
Journal:  Clin Genet       Date:  1996-12       Impact factor: 4.438

4.  Encouraging patients to undergo prenatal genetic counseling before the day of amniocentesis. Its effect on the use of amniocentesis.

Authors:  R P Lorenz; J J Botti; C M Schmidt; R L Ladda
Journal:  J Reprod Med       Date:  1985-12       Impact factor: 0.142

5.  Genetic counseling before prenatal diagnosis for advanced maternal age: an important medical safeguard.

Authors:  S P Rubin; J Malin; J Maidman
Journal:  Obstet Gynecol       Date:  1983-08       Impact factor: 7.661

6.  A randomized trial comparing alternative approaches to prenatal diagnosis counseling in advanced maternal age patients.

Authors:  A G W Hunter; M Cappelli; L Humphreys; J E Allanson; T T Chiu; C Peeters; D Moher; A Zimak
Journal:  Clin Genet       Date:  2005-04       Impact factor: 4.438

7.  Nuchal translucency and the acceptance of invasive prenatal chromosomal diagnosis in women aged 35 and older.

Authors:  M A Zoppi; R M Ibba; M Putzolu; M Floris; G Monni
Journal:  Obstet Gynecol       Date:  2001-06       Impact factor: 7.661

8.  The importance of genetic counseling before amniocentesis.

Authors:  G M Cohn; M Gould; R C Miller; J Habecker-Green; C J Macri; M L Gimovsky
Journal:  J Perinatol       Date:  1996 Sep-Oct       Impact factor: 2.521

9.  Factors that affect the decision to undergo amniocentesis in women with normal Down syndrome screening results: it is all about the age.

Authors:  Julia Grinshpun-Cohen; Talya Miron-Shatz; Liat Ries-Levavi; Elon Pras
Journal:  Health Expect       Date:  2014-05-12       Impact factor: 3.377

10.  Why, and how, mixed methods research is undertaken in health services research in England: a mixed methods study.

Authors:  Alicia O'Cathain; Elizabeth Murphy; Jon Nicholl
Journal:  BMC Health Serv Res       Date:  2007-06-14       Impact factor: 2.655

View more
  4 in total

1.  A survey on awareness of genetic counseling for non-invasive prenatal testing: the first year experience in Japan.

Authors:  Junko Yotsumoto; Akihiko Sekizawa; Nobuhiro Suzumori; Takahiro Yamada; Osamu Samura; Miyuki Nishiyama; Kiyonori Miura; Hideaki Sawai; Jun Murotsuki; Michihiro Kitagawa; Yoshimasa Kamei; Hideaki Masuzaki; Fumiki Hirahara; Toshiaki Endo; Akimune Fukushima; Akira Namba; Hisao Osada; Yasuyo Kasai; Atsushi Watanabe; Yukiko Katagiri; Naoki Takeshita; Masaki Ogawa; Takashi Okai; Shunichiro Izumi; Haruka Hamanoue; Mayuko Inuzuka; Kazufumi Haino; Naoki Hamajima; Haruki Nishizawa; Yoko Okamoto; Hiroaki Nakamura; Takeshi Kanegawa; Jun Yoshimatsu; Shinya Tairaku; Katsuhiko Naruse; Hisashi Masuyama; Maki Hyodo; Takashi Kaji; Kazuhisa Maeda; Keiichi Matsubara; Masanobu Ogawa; Toshiyuki Yoshizato; Takashi Ohba; Yukie Kawano; Haruhiko Sago
Journal:  J Hum Genet       Date:  2016-09-08       Impact factor: 3.172

2.  Clinical features and pregnancy outcomes of women with abnormal cell-free fetal DNA test results.

Authors:  Qin Zhou; Zhi-Ping Zhu; Bin Zhang; Bin Yu; Zheng-Mao Cai; Pei Yuan
Journal:  Ann Transl Med       Date:  2019-07

3.  The assessment of combined karyotype analysis and chromosomal microarray in pregnant women of advanced maternal age: a multicenter study.

Authors:  Ye Shi; Jun Ma; Ying Xue; Jing Wang; Bin Yu; Ting Wang
Journal:  Ann Transl Med       Date:  2019-07

4.  Prenatal Diagnosis Nomograms: A Novel Tool to Predict Fetal Chromosomal Abnormalities in High-Risk Patients.

Authors:  Yangzi Zhou; Zixuan Song; Lu Sun; Yuting Wang; Xiting Lin; Dandan Zhang
Journal:  Risk Manag Healthc Policy       Date:  2021-11-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.